A comprehensive view of Viiv Healthcare Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

The FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine) for adolescents aged 12 and above for the treatment of HIV-1 infection; Dovato offers a single-tablet, two-drug oral regimen for HIV therapy
Published: April 08, 2024 by GSK Group (GlaxoSmithKline)
ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva cabotegravir + rilpivirine compared to daily oral therapy in individuals with HIV who have adherence challenges
Published: March 06, 2024 by GSK Group (GlaxoSmithKline)
ViiV Healthcare reports positive findings from Phase 1 study of a new ultra-long acting cabotegravir formulation for HIV treatment, potentially enabling dosing intervals of at least four months; data support further development of CAB-ULA
Published: March 04, 2024 by GSK Group (GlaxoSmithKline)
ViiV Healthcare's long-acting injectable antiretroviral treatment for HIV, Cabenuva, shows superior efficacy in maintaining viral load suppression compared to daily oral therapy; results come from interim results from Phase 3 trial
Published: February 21, 2024 by GSK Group (GlaxoSmithKline)
ViiV Healthcare announces new blister packaging option now available in US for Dovato, a complete regimen to treat HIV-1 infection; blister pack supports treatment discretion and portability for some people living with HIV
Published: February 05, 2024 by Business Wire

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count